
Penumbra (PEN) Stock Forecast & Price Target
Penumbra (PEN) Analyst Ratings
Bulls say
Penumbra is being acquired by Boston Scientific in a stock-and-cash transaction that values the company's enterprise value at $14.5B. This acquisition is a strategic move for Boston Scientific, as it gains access to Penumbra's differentiated technology platform and its strong market position in the high-growth VTE market. Additionally, we expect to see continued growth and innovation in Penumbra's neurovascular franchise, which will likely drive further adoption and market share. However, potential changes in reimbursement could have a negative impact on Penumbra's business. Overall, we believe Boston Scientific is paying a fair price for Penumbra and do not anticipate any other bidders to emerge.
Bears say
Penumbra is facing competition in the neurovascular market from larger and more established companies like Medtronic, Stryker, Boston Scientific, Johnson & Johnson, and Terumo. The recent acquisition by Boston Scientific at a high valuation highlights the company's market potential and growth opportunities in the peripheral vascular space. However, risks to our neutral rating include macroeconomic headwinds and potential for future competition and slippage in product timelines.
This aggregate rating is based on analysts' research of Penumbra and is not a guaranteed prediction by Public.com or investment advice.
Penumbra (PEN) Analyst Forecast & Price Prediction
Start investing in Penumbra (PEN)
Order type
Buy in
Order amount
Est. shares
0 shares